A tyrosine kinase inhibitor lenvatinib is oxidized by human cytochromes P450 and aldehyde oxidase in vitro

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F18%3APU136064" target="_blank" >RIV/00216305:26620/18:PU136064 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1002/2211-5463.12453" target="_blank" >https://doi.org/10.1002/2211-5463.12453</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
A tyrosine kinase inhibitor lenvatinib is oxidized by human cytochromes P450 and aldehyde oxidase in vitro
Original language description
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR1-VEGFR3), fibroblast growth factor receptors (FGFR1-FGFR4), platelet-derived growth factor receptor (PDGFR) a, rearranged during transfection (RET), and v-kit (KIT) signalling networks implicated in tumor angiogenesis. It is used for treatment of certain tumors of the thyroid gland and metastatic renal cell carcinoma. Based on preliminary studies using human hepatic microsomes, lenvatinib was suggested to be oxidized by cytochromes P450 (CYPs), mainly by CYP3A4, to its O-demethylated metabolite, a desmethylated form of lenvatinib. However, no direct prove of this suggestion was demonstrated. Therefore, the aim of this study was to investigate the metabolism of lenvatinib by human microsomal enzymes in vitro in detail. Utilizing human hepatic microsomes and recombinant CYPs expressed in Supersomes TM, the metabolism of lenvatinib was studied. The lenvatinib metabolites were separa
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)